SAFETY, EFFICACY AND IMMUNOGENICITY OF VB10.16, A THERAPEUTIC DNA VACCINE TARGETING HUMAN PAPILLOMAVIRUS (HPV) 16 E6 AND E7 PROTEINS FOR HIGH GRADE CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN 2/3): 6-MONTH DATA FROM AN EXPLORATORY OPEN-LABEL PHASE I/2A TRIAL | Atlanta, April 2019
1674
portfolio_page-template-default,single,single-portfolio_page,postid-1674,bridge-core-1.0.4,ajax_updown_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-,qode-theme-ver-18.0.8,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,wpb-js-composer js-comp-ver-5.7,vc_responsive

SAFETY, EFFICACY AND IMMUNOGENICITY OF VB10.16, A THERAPEUTIC DNA VACCINE TARGETING HUMAN PAPILLOMAVIRUS (HPV) 16 E6 AND E7 PROTEINS FOR HIGH GRADE CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN 2/3): 6-MONTH DATA FROM AN EXPLORATORY OPEN-LABEL PHASE I/2A TRIAL

Atlanta, April 2019